The drug eluting balloon (DES) market offers significant benefits for patients requiring vascular interventions. DES technology involves coating angioplasty balloons with an anti-proliferative drug to prevent restenosis post angioplasty. DES balloons effectively deliver drugs to treat coronary and peripheral arterial diseases. They provide superior clinical outcomes compared to uncoated balloons and bare-metal stents. DES therapy has minimal instrument invasiveness and reduces risk of stent thrombosis. This has boosted the uptake of DES among healthcare professionals for treating atherosclerosis.

The Global Drug Eluting Balloon Market is estimated to be valued at US$ 769.29 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Drug Eluting Balloon Market Size are Oracle Corporation (NetSuite Inc.), BatchMaster Software, Columbus Manufacturing, Aquilon Software, CompuTec S.A.(ProcessForce), Datacor Chempax, DESKERA, ERPAG, Fishbowl, Intellect, SAGE GROUP plc, and VAI - Vormittag Associates, Inc. The rising geriatric population suffering from cardiology diseases is a major factor fueling demand for DES therapy. With increasing life expectancy, the risk of vascular diseases has grown globally. Technological advancements in catheter materials and drug coatings have made DES safer and more efficacious for patients.

Market trends

Innovation is a key trend with players developing novel drug infusion methods and bioresorbable polymers. They are designing DES specifically for peripheral interventions to expand treatment options. Adoption of robotics and AI is allowing more personalized therapy planning and treatment monitoring. Increased healthcare spending in emerging nations will facilitate market penetration.

Market Opportunities

One major opportunity is the large untapped market in rural and semi-urban regions. Community health programs can boost awareness about DES and encourage people to seek early intervention. Collaborations between device makers, healthcare providers and insurance companies can make DES therapy more accessible and affordable. Regulatory approvals for new drug-device indications will further enlarge the clinical plateau for DES technology.

Impact of COVID-19 on Drug Eluting Balloon Market
The COVID-19 pandemic has adversely impacted the growth of the drug eluting balloon market. The shutdown of manufacturing facilities and restrictions on non-essential medical procedures led to supply chain disruptions and a decline in the number of angioplasty procedures performed during the initial months of the pandemic. However, drug-eluting balloons are increasingly being used to treat patients with cardiovascular diseases as a minimally invasive procedure. With the resumption of healthcare services and ongoing vaccination drives, the demand for drug-eluting balloons is expected to rise in the post-pandemic period.

The pandemic highlighted the crucial role of drug-eluting balloons in treating patients with cardiovascular ailments. However, it also posed unique challenges for market players. Factors like maintaining sterilization protocols, ensuring an uninterrupted supply of materials, implementing work from home policies for employees impacted operations. Going forward, companies need to diversify their supplier base, focus on digital technologies for remote monitoring of patients, and collaborate with hospitals, private institutions, and governments to strengthen healthcare infrastructure. Adopting aggressive marketing strategies in the growing Asian markets and investing in RD for next-gen products can help overcome disruptions in the future.

Geographical Regions with High Drug Eluting Balloon Market Concentration
Europe accounts for the largest share of the global drug eluting balloon market in terms of value. Factors such as the rising geriatric population, increasing incidence of cardiovascular diseases, developed healthcare infrastructure, and supportive government policies have boosted market growth in the region. Moreover, the presence of leading manufacturers and the availability of advanced medical facilities for angioplasty have made Europe an attractive market for drug-eluting balloons.

Asia Pacific is currently the fastest-growing region for drug eluting balloons and is expected to witness high growth rates over the forecast period. Rising healthcare expenditures, growing medical tourism industry, rising urbanization, and increasing awareness about minimally invasive treatments are some key factors driving the Asia Pacific market. Additionally, countries like China and India offer large patient pools and provide lucrative growth opportunities for international and domestic market players.

Fastest Growing Region in the Drug Eluting Balloon Market

Asia Pacific is projected to be the fastest-growing region in the global drug eluting balloon market during the forecast period. This can be attributed to factors such as the rising geriatric population, growing prevalence of cardiac disorders, increasing healthcare spending, and improving medical infrastructure in emerging Asian countries. Further, favorable government policies to promote medical device manufacturing are encouraging domestic players as well as multinational companies to expand their footprint in Asia Pacific.

The presence of medical tourism destinations like India, Thailand, and Singapore coupled with low treatment costs compared to Western countries has been attracting patients from across the world. Additionally, rising lifestyle diseases, rapidly changing eating habits, growing obesity rate, and increasing adoption of technologically advanced minimally invasive procedures are fueling the demand for drug-eluting balloons in Asia Pacific.

Explore Our More Blogs on Drug Eluting Balloon Market